[1] Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis, 2014, 73: 2160-2167
[2] Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. Q J Med, 1982, 51(204): 469-480
[3] Mcdermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell, 1999, 97(1): 133-144
[4] Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum, 2008, 58(1): 273-283
[5] Rigante D, Lopalco G, Vitale A, et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol, 2014, 33(9): 1197-207
[6] Ueda N, Ida H, Washio M, et al. Clinical and genetic features of patients with TNFRSF1A variants in Japan: findings of a nationwide survey. Arthritis Rheumatol, 2016, 68(11): 2760-2771
[7] Van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med, 2005, 5(3): 87-98
[8] Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentrestudy. Clin Res Cardiol, 2012, 101(7): 525-531
[9] Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore), 2002, 81(5): 349-368
[10] 李俊, 赵鸿, 霍娜, 等. 肿瘤坏死因子受体相关周期性发热综合征1例报告. 中国实用内科杂志, 2016, 36(9): 819-821
[11] Aganna E, Zeharia A, Hitman GA, et al. An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum, 2002, 46(1): 245-249
[12] Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis, 2015, 74(5): 799-805
[13] ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis, 2015, 74(9): 1636-1644
[14] Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: A prospective, open-label, dose-escalation study. Arthritis Rheum, 2012, 64(3): 908-913
[15] Hamsen F, Müntjes C, Kampmann W, et al. Atypical clinical presentation of a severe Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) without mutation in the TNFRSF1A gene and good response to anakinra. Case report of a ten year old girl with fever, skin edema and abdominal pain (AID-registry). PediatrRheumatol Online J, 2015, 13(Suppl1): P43
[16] Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome(TRAPS): an open-label, phase II study. Ann Rheum Dis, 2017, 76(1): 173-178
[17] Akasbi N, Soyfoo MS. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report. Eur J Rheumatol, 2015, 2(1): 35-36 |
